Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
US Department of Justice
Federal Trade Commission
Teva

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207968

  Try a free trial


See Plans and Pricing

« Back to Dashboard

NDA 207968 describes JADENU SPRINKLE, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the JADENU SPRINKLE profile page.

The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 207968
Tradename:JADENU SPRINKLE
Applicant:Novartis Pharms Corp
Ingredient:deferasirox
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 207968
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU SPRINKLE deferasirox GRANULE;ORAL 207968 NDA Novartis Pharmaceuticals Corporation 0078-0713 0078-0713-15 30 PACKET in 1 CARTON (0078-0713-15) > 1 GRANULE in 1 PACKET (0078-0713-19)
JADENU SPRINKLE deferasirox GRANULE;ORAL 207968 NDA Novartis Pharmaceuticals Corporation 0078-0720 0078-0720-15 30 PACKET in 1 CARTON (0078-0720-15) > 1 GRANULE in 1 PACKET (0078-0720-19)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength90MG
Approval Date:May 18, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 12, 2021
Regulatory Exclusivity Use:INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
Patent:  Try a Free TrialPatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength180MG
Approval Date:May 18, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 12, 2021
Regulatory Exclusivity Use:INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD

Expired US Patents for NDA 207968

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-001 May 18, 2017   Try a Free Trial   Try a Free Trial
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-003 May 18, 2017   Try a Free Trial   Try a Free Trial
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-002 May 18, 2017   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Argus Health
Colorcon
Farmers Insurance
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.